NEW YORK, Aug. 22, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved record-breaking patch sales and record-breaking gross profit, driven by the success of its new sales model coupled with key strategic initiatives involving commercial expansion and clinical activities. These results highlight the company’s growing market presence and commitment to innovation in the cardiac diagnostics space.
“I’m proud of the significant progress Acarix has made over the last quarter,” stated Aamir Mahmood, Acarix President and CEO. “The success we experienced in Q2, including record-breaking patch sales and a substantial increase in gross profit, is a clear indicator of our strategy’s effectiveness. This validates our commitment to innovation, operational excellence, and value creation as we continue to strengthen our market position with the CADScor System and expand our impact in cardiac diagnostics.”
Key Highlights
Second quarter 2024 compared to the same period in 2023
First half of 2024 compared to the same period in 2023
Link to the report : https://www.acarix.com/for-investors/financial-reports-and-calendar
About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com
Media Contact: Jennifer Anderson, jennifer.anderson@acarix.com
SOURCE Acarix
With ongoing investigation into PF and other diseases that inflame and permanently scar lung tissue,…
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2024) - Revitalist Lifestyle and Wellness Ltd. (CSE:…
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- As open enrollment approaches and millions of Americans choose…
"Care That Moves You" Part of System-wide Commitment to Holistic Health, Healthy Exercise and Social…
Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more…
Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than…